Increase/Decrease in Cash: The total change in cash for the company over the given period.
Genmab A/S (GNMSF) had Increase/Decrease in Cash of $381.00M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$1.02B |
|
$401.00M |
|
$58.00M |
|
$964.00M |
|
$563.00M |
|
$459.00M |
|
$23.00M |
|
$482.00M |
|
$482.00M |
|
$401.00M |
|
$401.00M |
|
$401.00M |
|
$401.00M |
|
$459.00M |
|
$477.00M |
|
61.60M |
|
62.07M |
|
$6.51 |
|
$6.46 |
|
| Balance Sheet Financials | |
$4.47B |
|
$145.00M |
|
$2.55B |
|
$7.02B |
|
$741.00M |
|
-- |
|
$529.00M |
|
$1.27B |
|
$5.75B |
|
$3.65B |
|
$5.75B |
|
64.21M |
|
| Cash Flow Statement Financials | |
$885.00M |
|
$-71.00M |
|
$-440.00M |
|
$1.38B |
|
$1.76B |
|
|
Increase/Decrease in Cash |
$381.00M |
$92.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
94.32% |
|
44.91% |
|
44.91% |
|
-- |
|
47.16% |
|
39.24% |
|
$861.00M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
4.14 |
|
0.98 |
|
92.11 |
|
6.97% |
|
10.99% |
|
5.71% |
|
6.97% |
|
$89.57 |
|
$13.87 |
|
$14.26 |
|